{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:53:22Z","timestamp":1792720402335,"version":"4.5.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Widespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent FDA statement regarding this safety concern. Objectives: We analyzed a cohort of ocrelizumab treated patients in our MS center to evaluate the incidence of drug-induced colitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present a critical review of the available literature on diagnosis and management of anti-CD20 induced colitis and display a case series of 3 suspected patients in our cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two patients met the full criteria for ocrelizumab-induced colitis, while a third partially met the criteria. Following symptomatic treatment and discontinuation of ocrelizumab, the patients showed favorable outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ocrelizumab-induced colitis is a rare, but severe adverse event. Its incidence may be higher than expected, reaching 1,95% in our cohort of MS patients. Further reporting of such cases is essential to broaden our understanding of this side effect.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1530438","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T05:17:42Z","timestamp":1738732662000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ocrelizumab-induced colitis\u2014critical review and case series from a Romanian cohort of MS patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Ileana Maria","family":"Vod\u0103","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad Eugen","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"R\u0103u\u021b\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ciucur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea Ioana","family":"Mu\u0219uroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Flavia","family":"Tomescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta Laura","family":"Hum\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Dobri\u021boiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Terecoas\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Negreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"32","author":"Syed","year":"2018","journal-title":"CNS Drugs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Kappos L; OPERA I and OPERA II clinical investigators. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/TCRM.S282390","article-title":"Ocrelizumab for the treatment of multiple sclerosis: safety, efficacy, and pharmacology","volume":"17","author":"Mancinelli","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.msard.2023.104763","article-title":"Anti-CD20 monoclonal antibody (mAb) therapy and colitis: a case series and review, multiple sclerosis and related disorders","volume":"75","author":"Tolaymat","year":"","journal-title":"Mult Scler Relat Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S913","DOI":"10.14309\/01.ajg.0000709112.86831.18","article-title":"S1766 Ocrelizumab-induced colitis: a case report","volume":"115","author":"Tuqan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e00742","DOI":"10.14309\/crj.0000000000000742","article-title":"Severe ocrelizumab-induced enterocolitis treated successfully with ustekinumab","volume":"9","author":"Shah","year":"2022","journal-title":"ACG Case Rep J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.20524\/aog.2021.0582","article-title":"Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis","volume":"34","author":"Barnes","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"766","DOI":"10.17235\/reed.2022.9152\/2022","article-title":"Crohn's disease induced by ocrelizumab in a patient with multiple sclerosis","volume":"114","author":"Carballo-Folgoso","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.gastro.2019.11.043","article-title":"P096 De novo colitis after ocrelizumab therapy","volume":"158","author":"Akram","year":"2020","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1093\/ibd\/izaa057","article-title":"First case of refractory colitis caused by Ocrelizumab","volume":"26","author":"Sunjaya","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"8858374","DOI":"10.1155\/2020\/8858378","article-title":"Ocrelizumab-induced severe colitis","volume":"2020","author":"Lee","year":"2020","journal-title":"Case Rep Gastrointest Med"},{"key":"ref14","author":"Elands","year":""},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.12998\/wjcc.v10.i8.2569","article-title":"Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: a case report and review of literature","volume":"10","author":"Au","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1186016","DOI":"10.3389\/fphar.2023.1186016","article-title":"Impact of anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review","volume":"14","author":"Quesada-Sim\u00f3","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"a032037","DOI":"10.1101\/cshperspect.a032037","article-title":"B-cell therapies in multiple sclerosis","volume":"9","author":"Sabatino","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/ecco-jcc\/jjw074","article-title":"Ulcerative colitis is characterized by a decrease in regulatory B cells","volume":"10","author":"Wang","year":"2016","journal-title":"J Crohns Colitis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1016\/j.febslet.2011.03.064","article-title":"Cytokines and effector T cell subsets causing autoimmune CNS disease","volume":"585","author":"Petermann","year":"2011","journal-title":"FEBS Lett"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/13524585221147635","article-title":"Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis","volume":"29","author":"Abbadessa","year":"2023","journal-title":"Mult Scler"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/13524585231195853","article-title":"Colitis in ocrelizumab-treated patients: the dilemma of causation versus association in immune-mediated iatrogenicity","volume":"29","author":"Abboud","year":"2023","journal-title":"Mult Scler"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: a new safety risk","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/his.15120","article-title":"Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis","volume":"84","author":"Challa","year":"2024","journal-title":"Histopathology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1007\/s00415-024-12553-4","article-title":"Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue","volume":"271","author":"Viti","year":"2024","journal-title":"J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1055\/a-2008-0979","article-title":"Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis","volume":"61","author":"Lieb","year":"2023","journal-title":"Z Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e252140","DOI":"10.1136\/bcr-2022-252140","article-title":"Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis","volume":"15","author":"Malloy","year":"2022","journal-title":"BMJ Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e52032","DOI":"10.7759\/cureus.52032","article-title":"Two cases of acute diverticulitis following Ocrelizumab infusion in patients with multiple sclerosis","volume":"16","author":"Vigilante","year":"2024","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.nerep.2021.100013","article-title":"Perforated diverticulitis associated with ocrelizumab infusion","volume":"1","author":"Mehta","year":"","journal-title":"Neuroimmunol Rep"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.14740\/gr1041w","article-title":"Anti-inflammatory biologics and anti-Tumoral immune therapies-associated colitis: a focused review of literature","volume":"11","author":"Zhou","year":"2018","journal-title":"Gastroenterology Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3748\/wjg.v18.i16.1871","article-title":"Colitis associated with biological agents","volume":"18","author":"Freeman","year":"2012","journal-title":"World J Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/hep.23238","article-title":"B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice","volume":"50","author":"Moritoki","year":"2009","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.4143\/crt.2020.406","article-title":"Crohn's disease following rituximab treatment for follicular lymphoma in a patient with synchronous gastric signet ring cells carcinoma: a case report and literature review","volume":"52","author":"Cavalcanti","year":"2020","journal-title":"Cancer Res Treat"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1002\/ibd.22963","article-title":"Rituximab-associated colitis","volume":"19","author":"Bhalme","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13730-018-0364-8","article-title":"Crohn\u2019s disease following rituximab treatment in a patient with refractory nephrotic syndrome","volume":"8","author":"Morita","year":"2019","journal-title":"CEN Case Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2018.02.030","article-title":"A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review","volume":"22","author":"Shahmohammadi","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S849","DOI":"10.14309\/00000434-201810001-01479","article-title":"Rituximab-associated colitis: an unusual case report: 1479","volume":"113","author":"Aggarwal","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1200\/JCO.2010.31.8899","article-title":"Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma","volume":"29","author":"Blombery","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2169\/internalmedicine.5119-20","article-title":"Rituximab-induced Ileocolitis in a patient with gastric MALToma: a case report and literature review","volume":"60","author":"Tsuzuki","year":"2021","journal-title":"Intern Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/ibd\/izz270","article-title":"Treatment of rituximab-induced Crohn's disease with Ustekinumab induction and long-term maintenance of remission","volume":"26","author":"Shankar","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cgh.2019.03.027","article-title":"De novo colitis associated with rituximab in 21 patients at a tertiary center","volume":"18","author":"Eckmann","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/gut.2007.138305","article-title":"Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease","volume":"57","author":"El Fassi","year":"2008","journal-title":"Gut"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","article-title":"Severe ulcerative colitis after rituximab therapy","volume":"126","author":"Ardelean","year":"2010","journal-title":"Pediatrics"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/ibd.20215","article-title":"Exacerbation of ulcerative colitis after rituximab salvage therapy","volume":"13","author":"Goetz","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/COC.0000000000000553","article-title":"Clinical features of rituximab-associated gastrointestinal toxicities","volume":"42","author":"Mallepally","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/17562848221115312","article-title":"Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations","volume":"15","author":"Bezzio","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"25860","DOI":"10.1073\/pnas.1905955116","article-title":"Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis","volume":"116","author":"Haupeltshofer","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1474-4422(19)30356-4","article-title":"The gut microbiome in neurological disorders","volume":"2","author":"Cryan","year":"","journal-title":"Lancet Neurol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.51495","article-title":"Multiple sclerosis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/s0140-6736(76)91972-3","article-title":"Small-bowel abnormalities in multiple sclerosis","volume":"2","author":"Lange","year":"1976","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"718220","DOI":"10.3389\/fimmu.2021.718220","article-title":"The gut-brain Axis in multiple sclerosis. Is its dysfunction a pathological trigger or a consequence of the disease?","volume":"12","author":"Parodi","year":"2021","journal-title":"Front Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1007\/BF02100148","article-title":"Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability","volume":"41","author":"Yacyshyn","year":"1996","journal-title":"Dig Dis Sci"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1038\/s41467-021-25768-0","article-title":"Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1017\/cjn.2024.21","article-title":"Hypogammaglobulinemia and infection risk in an Ocrelizumab-treated multiple sclerosis cohort","volume":"51","author":"Nobile","year":"2024","journal-title":"Can J Neurol Sci"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1159\/000338131","article-title":"Biologic therapies: lessons from multiple sclerosis","volume":"30","author":"Ghosh","year":"2012","journal-title":"Dig Dis"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/acn3.50862","article-title":"Environmental and genetic risk factors for MS: an integrated review","volume":"6","author":"Waubant","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241303480","article-title":"Immune-mediated colitis: a class effect with anti-CD2O agents used to treat MS?","volume":"3480","author":"Viti","year":"2024","journal-title":"Mult Scler"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/17562864221092092","article-title":"Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study","volume":"15","author":"Moser","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e16859","DOI":"10.7759\/cureus.16859","article-title":"A review of four practice guidelines of inflammatory bowel disease","volume":"13","author":"Okobi","year":"2021","journal-title":"Cureus"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.cgh.2019.02.043","article-title":"Canadian Association of Gastroenterology clinical practice guideline for the Management of Luminal Crohn's disease","volume":"17","author":"Panaccione","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/MCG.0000000000000660","article-title":"Review team:. World gastroenterology organisation global guidelines inflammatory bowel disease: update august 2015","volume":"50","author":"Bernstein","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"Singh S on behalf of theAGA institute clinical guidelines committee. AGA clinical practice guidelines on the Management of Moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3399\/bjgp18X699341","article-title":"Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care","volume":"68","author":"Barrett","year":"2018","journal-title":"Br J Gen Pract"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1756283X11405250","article-title":"Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease","volume":"4","author":"Williams","year":"2011","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1530438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T05:17:46Z","timestamp":1738732666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1530438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":68,"alternative-id":["10.3389\/fneur.2025.1530438"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1530438","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"article-number":"1530438"}}